EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

Polymorphisms in CYP3A5, CYP3A4, and ABCB1 genes: implications for calcineurin inhibitors therapy in hematopoietic cell transplantation recipients—a systematic review

Luiz Carlos da Costa-Junior, Daniely Regina Freitas-Alves, Amanda Melo Leite Leão, Hayra de Andrade Vieira Monteiro, Rita de Cássia Barbosa da Silva Tavares, Maria Claudia Rodrigues Moreira, Marília Berlofa Visacri, Teresa de Souza Fernandez, Paulo Caleb Júnior de Lima Santos

Frontiers in Pharmacology · 16.07.2025 · 16

DOI: 10.3389/fphar.2025.1569353 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Frontiers in Pharmacology, online erschienen am 16.07.2025. Verfasst von Luiz Carlos da Costa-Junior und 8 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate Program in Medical Sciences, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Conselho Nacional de Desenvolvimento Científico e Tecnológico, Coordenação de Aperfeiçoamento de Pessoal de Nível Superior, Fundação de Amparo à Pesquisa do Estado de São Paulo.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This systematic review assessed the impact of CYP3A5 , CYP3A4 , and ABCB1 polymorphisms on the pharmacokinetics and clinical outcomes of calcineurin inhibitors in hematopoietic cell transplantation (HCT) recipients. Following PRISMA 2020 guidelines, the protocol was registered in PROSPERO (CRD42024517094). A comprehensive search in PubMed, BVS, Scopus, Web of Science, Embase, and Cochrane databases (2013–2024) identified observational studies focusing on tacrolimus or cyclosporine and the specified polymorphisms. Studies on non-human subjects, solid organ transplants, pharmacokinetic models, and drug interactions were excluded. Narrative synthesis was employed due to heterogeneity, and study quality was evaluated using the Newcastle–Ottawa Scale (NOS) and STREGA guidelines. Of 301 records, 11 studies met inclusion criteria, predominantly retrospective and involving adult populations, with sample sizes ranging from 20 to 420 HCT recipients from the USA, Japan, and France. Outcomes included drug levels, median concentration/dose (C/D) ratio, therapeutic index, and clinical endpoints such as graft-versus-host disease (GVHD) and acute kidney injury (AKI). CYP3A5*3 (rs776746) significantly influenced tacrolimus levels, C/D ratio, and clinical outcomes, highlighting its potential as a pharmacogenetic biomarker. CYP3A4 and ABCB1 polymorphisms demonstrated limited effects on tacrolimus pharmacokinetics and no significant clinical impact. Methodological quality was high, with 55% of studies achieving the maximum NOS score, although gaps in error rates and population modeling were noted. Limitations include variability in outcomes precluding meta-analysis, a small number of studies, particularly on cyclosporine, and insufficient data on CYP3A4 and ABCB1 . Further research is necessary to validate findings. Systematic Review Registration https://www.crd.york.ac.uk/PROSPERO/view/CRD42024517094 , PROSPERO, CRD42024599998.

Schlagwörter

Stichwörter der Autor:innen

ABCB1CYP3A4CYP3A5calcineurin inhibitorshematopoietic cell transplantation

Autor:innen und Institutionen

  • Postgraduate Program in Medical Sciences, Faculdade de Medicina da Universidade de São Paulo (FMUSP), São Paulo, Brazil.
  • Bone Marrow Transplant Center, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
  • Escola Nacional de Saúde Pública Sérgio Arouca, Fundação Oswaldo Cruz (ENSP-FIOCRUZ), Rio de Janeiro, Brazil.
  • Escola de Ciências da Saúde, Universidade do Grande Rio (Unigranrio), Duque de Caxias, Brazil.
  • Cytogenetic Laboratory, Cell and Gene Therapy Program, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.
  • Clinical Research Division, Instituto Nacional de Câncer (INCA), Rio de Janeiro, Brazil.

Förderung

  • Conselho Nacional de Desenvolvimento Científico e Tecnológico
  • Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
  • Fundação de Amparo à Pesquisa do Estado de São Paulo
  • Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro

Zitieren

APA

da Costa-Junior, L. C., Freitas-Alves, D. R., Leão, A. M. L., Monteiro, H. A. V., Tavares, R. C. B. D. S., Moreira, M. C. R., Visacri, M. B., Fernandez, T. S., & Santos, P. C. J. L. (2025). Polymorphisms in CYP3A5, CYP3A4, and ABCB1 genes: implications for calcineurin inhibitors therapy in hematopoietic cell transplantation recipients—a systematic review. Frontiers in Pharmacology, 16. https://doi.org/10.3389/fphar.2025.1569353

Vancouver

da Costa-Junior LC, Freitas-Alves DR, Leão AML, Monteiro HAV, Tavares RCBDS, Moreira MCR, et al. Polymorphisms in CYP3A5, CYP3A4, and ABCB1 genes: implications for calcineurin inhibitors therapy in hematopoietic cell transplantation recipients—a systematic review. Frontiers in Pharmacology. 2025;16. doi:10.3389/fphar.2025.1569353

BibTeX
@article{daCostaJunior2025,
  author = {da Costa-Junior, Luiz Carlos and Freitas-Alves, Daniely Regina and Leão, Amanda Melo Leite and Monteiro, Hayra de Andrade Vieira and Tavares, Rita de Cássia Barbosa da Silva and Moreira, Maria Claudia Rodrigues and Visacri, Marília Berlofa and Fernandez, Teresa de Souza and Santos, Paulo Caleb Júnior de Lima},
  title = {Polymorphisms in CYP3A5, CYP3A4, and ABCB1 genes: implications for calcineurin inhibitors therapy in hematopoietic cell transplantation recipients—a systematic review},
  journal = {Frontiers in Pharmacology},
  year = {2025},
  volume = {16},
  doi = {10.3389/fphar.2025.1569353}
}
Kostenlos starten →